Navigation Links
Future diabetes treatment may use resveratrol to target the brain
Date:10/6/2009

Chevy Chase, MDResveratrol, a molecule found in red grapes, has been shown to improve diabetes when delivered orally to rodents. Until now, however, little has been known about how these beneficial changes are mediated in the body. A new study accepted for publication in Endocrinology, a journal of The Endocrine Society, shows that the brain plays a key role in mediating resveratrol's anti-diabetic actions, potentially paving the way for future orally-delivered diabetes medications that target the brain.

Resveratrol activates sirtuins, a class of proteins that are thought to underlie many of the beneficial effects of calorie restriction. Previous studies in mice have provided compelling evidence that when sirtuins are activated by resveratrol, diabetes is improved. Sirtuin activators are now being tested in humans as anti-diabetic compounds.

Sirtuins are expressed virtually everywhere throughout the body and until now, little has been known about what tissues mediate resveratrol's beneficial effects. Knowing where in the body the beneficial effects of activated sirtuins are mediated could help in the development of more effective targeted diabetes medications.

"We know that sirtuins are expressed in parts of the brain known to govern glucose metabolism, so we hypothesized that the brain could be mediating resveratrol's anti-diabetic actions," said Roberto Coppari, PhD, of the University of Texas Southwestern Medical Center and co-author of the study. "To test the hypothesis, we assessed the metabolic consequences of delivering resveratrol directly into the brain of diabetic mice. We found that resveratrol did activate sirtuins in the brain of these mice which resulted in improving their high levels of blood sugar and insulin."

"These findings may lead to new strategies in the fight against type 2 diabetes," said Coppari. "By knowing that the brain mediates resveratrol's anti-diabetic actions, industry can now focus on developing sirtuin activators that directly target the brain. When orally-delivered, these drugs will likely improve diabetes without affecting the other organs in which activation of sirtuins may not always be beneficial."


'/>"/>

Contact: Aaron Lohr
alohr@endo-society.org
240-482-1380
The Endocrine Society
Source:Eurekalert

Related medicine news :

1. Terumo Heart, Inc.'s DuraHeart™ Left-Ventricular Assist System Featured at Future of Health Technology Summit
2. Where surgery was the standard, casting may be the future
3. Obese Middle-Aged Women Face Unhealthy Future
4. Country United symposium explores collaborative future of military medicine
5. Norm Augustine to keynote symposium on accelerators for Americas future
6. Call for Proposals for Partners Investing in Nursings Future
7. Kidney Injury While Hospitalized May Lead to Future Dialysis
8. Future of Autos, Future of Health Care to Be Examined by the Michigan State Medical Society and the Michigan Dental Association
9. The future of schizophrenia
10. Harold Hank Gardner M.D. Named in the Future Health 100
11. Lord Stevens Commission Publishes Roadmap to Ensure Future of Equestrian Sport
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2017)... (PRWEB) , ... July 25, 2017 , ... ... Winner for its Product Innovation in the prestigious CEO World Awards®. The coveted ... performance, new products and services, CEO case studies, corporate social responsibility, and milestones ...
(Date:7/25/2017)... ... July 25, 2017 , ... SignatureCare Emergency Center – South Austin is ... 24 Hours a day. , The Emergency Room opened early March, ... open four months now and things are running smoothly,” said Aaron Braun, SignatureCare Emergency ...
(Date:7/24/2017)... PARK (PRWEB) , ... July 24, 2017 , ... Engineers ... is bio-compatible, because it produces the same kind of electrical energy that the body ... the form of moving electrons. This flow of electrons out of the battery is ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... kklaproth(at)robinsmorton(dot)com , Robins & Morton, Perkins Will, Newcomb & Boyd, Walter P ... of the new Destination Medical Building located at Mayo Clinic in Jacksonville, ...
(Date:7/24/2017)... ... July 24, 2017 , ... Cheerag D. Upadhyaya , ... Marion Bloch Neuroscience Institute (SLMBNI), part of Saint Luke’s Health System . ... , Cheerag D. Upadhyaya, MD. M.Sc., FAANS joins Stanley P. Fisher, M.D., ...
Breaking Medicine News(10 mins):
(Date:7/24/2017)... , July 24, 2017 IBM (NYSE: IBM ... Magic Quadrant for Solid-State Arrays (SSA) for the fourth year ... According to Gartner, "Vendors in the Leaders quadrant have ... of Vision. A vendor in the Leaders quadrant has the ... drive the acceptance of new technologies. These vendors demonstrate a ...
(Date:7/24/2017)... 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO ... quarter 2017 operating results on Monday, August 7, 2017 ... at 5:00 p.m. ET. ... live broadcast of the conference call by dialing 877-201-0168 ... 51641230 approximately 15 minutes prior to the call. A ...
(Date:7/21/2017)... and EDMONTON, Alberta ... ) scientists and the University of Alberta in ... new data in Nature,s partner journal, Schizophrenia 1 ... helped predict instances of schizophrenia with 74% accuracy. ... the severity of specific symptoms in schizophrenia patients ...
Breaking Medicine Technology: